The clinical failure of these vaccine therapies was attributed to the single targeting of the envelope antigen, produced in high quantity in CHB patients.
The clinical failure of these vaccine therapieswas attributed to the single targeting of the envelopeantigen, produced in high quantity in CHB patients.